Risk of Diabetes Mellitus in Persons with and without HIV: A Danish Nationwide Population-Based Cohort Study

Line D. Rasmussen1*, Elisabeth R. Mathiesen2, Gitte Kronborg3, Court Pedersen1, Jan Gerstoft4, Niels Obel4

1 Department of Infectious Diseases, Odense University Hospital, Odense, Denmark, 2 Department of Endocrinology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, 3 Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, Denmark, 4 Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

Abstract

Objective: In a nationwide, population-based cohort study we assessed the risk of diabetes mellitus (DM) in HIV-infected individuals compared with the general population, and evaluated the impact of risk factors for DM in HIV-infected individuals.

Methods: We identified 4,984 Danish-born HIV-infected individuals from the Danish HIV Cohort Study and a Danish born population-based age- and gender-matched comparison cohort of 19,936 individuals (study period: 1996–2009). Data on DM was obtained from the Danish National Hospital Registry and the Danish National Prescription Registry. Incidence rate ratios (IRR) and impact of risk factors including exposure to Highly Active Antiretroviral Therapy (HAART) and antiretroviral drugs were estimated by Poisson regression analyses.

Results: In the period 1996–1999 risk of DM was higher in HIV-infected individuals compared to the comparison cohort (adjusted IRR: 2.83; 95%CI: 1.57–5.09), both before (adjusted IRR: 2.40; 95%CI: 1.03–5.62) and after HAART initiation (adjusted IRR: 3.24; 95% CI: 1.42–7.39). In the period 1999–2010 the risk of DM in HIV-infected individuals did not differ from that of the comparison cohort (adjusted IRR: 0.90; 95% CI: 0.72–1.13), although the risk was decreased before HAART-initiation (adjusted IRR: 0.45; 95%CI: 0.21–0.96). Increasing age, BMI and the presence of lipoatrophy increased the risk of DM, as did exposure to indinavir, saquinavir, stavudine and didanosine.

Conclusion: Native HIV–infected individuals do not have an increased risk of developing DM compared to a native background population after year 1998. Some antiretroviral drugs, not used in modern antiretroviral treatment, seem to increase the risk of DM.

Introduction

Since the late nineties, studies on HIV-infected individuals have reported a wide spectrum of metabolic alterations associated with Highly Active Antiretroviral therapy (HAART) including changes in glucose homeostasis and fat redistribution [1–3]. As the lifespan of HIV-infected individuals have been prolonged, due to a decline in HIV-associated morbidity and mortality on account of HAART [4–5], such metabolic imbalances could affect the long-term prognosis due to progression of insulin resistance to diabetes mellitus (DM) and subsequent risk of end-organ disease.

In addition to the well known risk factors for DM [6], immunodeficiency, lipodystrophy, socioeconomic class, concurrent hepatitis C infection (HCV), and drug abuse have been described as possible risk factors [3,7–13]. Since the US Food and Drug Administration in 1997 issued a warning on the diabetogenic effects of protease inhibitors (PIs), risk of glucose alterations in HIV-infected individuals have been largely attributed to this drug class [14–18]. Additionally, nucleotide reverse transcriptase inhibitors (NRTIs) have been proposed to accelerate the pathogenic mechanisms of DM development, but the data are limited [7,9–11,18–22]. As insulin resistance and impaired glucose
tolerance induced by HAART might act as a precursor of DM, risk of DM might be increased in the HAART era. Several studies have addressed the risk of DM in the HIV-infected population [7,9, 11, 18–19, 21–24], but the results are conflicting and the majority of the studies are hampered by mixed ethnicity and lack of a comparison cohort from the general population.

We aimed to conduct a nationwide, population-based cohort study in the period 1 January 1996 to 1 January 2010 to investigate the risk of DM in HIV-infected individuals compared to that of the general population. To evaluate the impact of certain risk factors we further examined the influence of age, body mass index (BMI), lipoatrophy, HAART and specific antiretroviral drugs on risk of DM in HIV-infected individuals.

Methods

Setting

As of 1 January 2010 Denmark had a population of 5.5 million, with an estimated HIV prevalence of 0.1% among adults [25–26]. Treatment of HIV infection is restricted to eight specialized centers, where patients are seen on an outpatient basis at intended intervals of 12 weeks. Antiretroviral treatment is provided free-of-charge. During the follow-up period of the study, national criteria for initiating HAART were HIV-related disease, acute HIV infection, pregnancy, CD4 cell count < 300 cells/μl, and, until 2001, plasma HIV-RNA > 100,000 copies/ml. HAART was defined as a treatment regimen of at least three antiretroviral drugs or a treatment regimen including a combination of a non-nucleoside reverse transcriptase inhibitor and a boosted protease inhibitor and/or integrase inhibitor. Structured treatment interruptions have generally not been used in Denmark.

Data Sources

We used the unique 10-digit civil registration number assigned to all individuals in Denmark at birth or upon immigration to link data from the following registers:

The Danish HIV Cohort Study (DHCS). DHCS, which has been described in detail elsewhere [27], is a nationwide, prospective, population-based cohort study of all Danish HIV-infected individuals treated in one of the above mentioned centers since 1 January 1995. DHCS is still ongoing, thus consecutively enrolling new HIV-infected individuals and immigrants with HIV infection. As all HIV-infected individuals are referred to one of the above mentioned centers at diagnosis, and HAART is only available in these centers, DHCS includes almost all individuals diagnosed with HIV in Denmark.

The Danish Civil Registration System (DCRS). DCRS, established in 1968, is a national registry which stores information on vital status, residency, and immigration/emigration for all Danish residents [28].

The Danish National Hospital Registry (DNHR). DNHR, established in 1977, records data on all patients discharged from non-psychiatric hospitals in Denmark. Diagnoses are coded according to the International Classification of Diseases [8th revision (ICD-8) until December 31 1993 and 10th revision (ICD-10) thereafter] [29]. Since 1995 data on outpatients and emergency patients have been included.

The Danish National Prescription Registry (DNPR). DNPR, established in 1994 by the Danish Medicines Agency at the National Board of Health [30], records individual-level data on all redeemed prescriptions dispensed at Danish community pharmacies with complete data since 1 January 1995. The register includes variables related to the drug user, prescriber and pharmacy as well as the dispensing such as date of dispensing, product code and name, Anatomical Therapeutic Chemical Classification (ATC) code, dosage form and strength.

Study Populations

HIV cohort. The HIV cohort consisted of all Danish born HIV-infected individuals, older than 16 years at HIV diagnosis, identified from DHCS. The index date was defined as the date of HIV diagnosis or January 1 1996 whichever was more recent. Individuals, with prevalent DM diagnoses at or a prescription of an anti-diabetic drug prior to index date, were excluded.

General population comparison cohort. The comparison cohort consisted of 4 age- and gender matched population controls for each HIV-infected individual identified from DCRS. Only Danish born individuals were selected. Additional criteria for inclusion included being alive and living in Denmark on index date, having no registration of DM in DNHR prior to index date and having no redeemed prescription of an anti-diabetic drug prior to index date. Index date for the comparison cohort was defined as the index date of the corresponding HIV-infected individual.

Outcome

We identified the first date an individual was registered with a DM code in DNHR or the date of first redemptions of a prescription of an anti-diabetic drug following index date and defined this as new-onset DM (ICD8 and ICD-10 diagnosis codes: 249.00–259.09, E10.0-E14.9; ATC codes for insulin and analogues, and oral anti-diabetic drugs: A10AB01-A10AE05, A10BA02-A10BX07 codes and descriptions are further provided in the Appendix S1 and S2). As the ICD8/ICD10 codes registered in DNHR defines DM as either insulin dependent DM (IDDM) or non-insulin-dependent (NIDDM), it is not possible to distinguish between type 1 and type 2 DM based on this information. We therefore defined Type 2 DM as individuals assigned a NIDDM code (E11/259), individuals assigned one of the three less specific DM forms (E12, E13, E14), or individuals who had ever redeemed a prescription of an oral anti-diabetic drug. This approach is in agreement with the approach used by Petersen et al [31]. We furthermore defined type 2DM as individuals who had redeemed prescriptions on insulin products but with no prior IDDM code (E10/249) or individuals with an IDDM code who had never initiated insulin therapy. Type 1 DM was defined as individuals with an IDDM code who initiated insulin therapy and did not fulfill any of the above mentioned criteria.

Confounding Variables

In Denmark the racial distribution in the HIV-infected population is different from that of the general population. As we had no access to racial data for the comparison cohort, we restricted the analyses to native (Danish born) individuals for both groups (HIV-infected individuals vs. comparison cohort). In the final model we included the following covariates to control for potential confounding: - Age (fitted as a time-updated variable- categorized in 9 age intervals, split at the ages 30, 35, 40, 45, 50, 55, 60, 65), gender and calendar year (categorized in 5 calendar intervals, split at 1 January 1999, 2001, 2004 and 2007). Analysis on HIV-infected individuals were further adjusted according to the presence of HCV and/or intravenous drug abuse (IDU) (IDU if registered as route of infection in DHCS and HCV defined as being seropositive for HCV and/or having a positive HCV RNA registered in DHCS - Hepatitis testing is performed routinely at the first visit). Data on height and weight at index date was extracted from DHCS and BMI was calculated and grouped as defined in the Appendix S3. Lipoatrophy was extracted from
DHCS as the first date an HIV-infected individual presented with lipodystrophy and introduced as a time-updated variable to evaluate the risk of DM prior to and after this date.

Statistical Analysis

Time was computed from index date until date of new-onset DM, date of death, emigration, lost to follow up or 1 January 2010, whichever occurred first. Cumulative incidence function was used to illustrate time to first occurrence of DM recognizing death as a competing risk. We used Poisson regression analysis to compute incidence rates (IR) and incidence rate ratios (IRR), as a measure of the relative risk, and 95% confidence intervals (CI), comparing the risk of DM in HIV-infected individuals with that of the comparison cohort. In a robustness analysis we restricted the outcome of the analyses to type 2 DM as defined in the above section, however, as this did not change the estimates substantially all further analysis were performed with DM as endpoint. The analyses were adjusted for potential confounding factors as described in the above section. Due to effect modification by calendar time, analysis comparing HIV-infected individuals and the comparison cohort individuals were analysed separately according to split in calendar time (time-updated variable). In the HIV-infected individuals risk of DM was assessed according to BMI level, age and lipodystrophy. To evaluate the impact of HAART on risk of DM we included date of HAART initiation as a time-updated variable and assessed the IRR of DM in the non-HAART period and the HAART period for the HIV-infected individuals compared to the comparison cohort individuals.

To estimate the impact of antiretroviral drugs (indinavir, saquinavir, stavudine, lopinavir, ritonavir, PI in general, and stavudine, zidovudine, didanosine, abacavir, tenofovir and lamivudine) on the risk of DM, we performed analyses in which only HIV-infected individuals initiating HAART were included. Time was calculated from date of HAART initiation. The first initiation of the specific drug was handled as a time-updated variable and assessed the IRR of DM in the non-HAART period and the HAART period for the HIV-infected individuals compared to the comparison cohort individuals.

In the period 1999–2010 we observed no increased risk of DM in HIV-infected individuals compared to the general population. However, in this period the risk was decreased prior to HAART initiation. In the years 1996–1998 the risk of DM was increased whereas in the years 1999–2010 the risk was decreased prior to HAART initiation. In the years 1996–1998 the risk of DM was increased prior to (adjusted IRR: 2.40; 95% CI: 1.03–5.62) and after HAART initiation (adjusted IRR: 3.24; 95% CI: 1.42–7.39) in the HIV-infected individuals than the comparison cohort. In contrast the risk of DM in the period 1999–2010 showed a statistically significant lower risk in the non-HAART period (adjusted IRR: 0.45; 95% CI: 0.21–0.96) and no increased risk after initiation of HAART (adjusted IRR: 1.00; 95% CI: 0.79–1.28) (Table 2).

HIV-infected individuals showed an increasing risk of DM with increasing age and BMI (Table 3). Also a diagnosis of lipodystrophy increased the risk substantially (adjusted IRR: 2.30; 95% CI: 1.39–3.80). We found no association between the cumulative effect of HAART and risk of diabetes (results not shown).

Initiation of stavudine (adjusted IRR: 1.81; 95% CI:1.19–2.75) and saquinavir (adjusted IRR: 1.53; 95% CI: 1.01–2.34) significantly increased the risk of DM compared with the HAART-period prior to initiation of these antiretroviral drugs, while a trend towards a higher incidence of DM in patients on indinavir (adjusted IRR: 1.38; 95% CI: 0.91–2.11) and didanosine (adjusted IRR: 1.52; 95% CI: 0.99–2.34) was found. Nelfinavir, atazanavir, ritonavir/PI in general, as well as zidovudine, abacavir, tenofovir and lamivudine did not increase the risk of DM (Table 4).

The performed robustness analysis, in which only cases defined as type 2 DM as previously defined was used as outcome, showed no major changes in the estimates of the relative risk (results not shown).

Discussion

In the period 1999–2010 we observed no increased risk of DM in HIV-infected individuals compared to the general population. However, in this period the risk was decreased prior to HAART initiation. In the years 1996–1998 the risk was increased irrespective of HAART treatment. Increasing age, BMI and the presence of lipodystrophy was associated with an increased risk of DM as was exposure to indinavir, saquinavir, stavudine and didanosine.

The strengths of our study include access to nationwide population-based cohorts with long and complete follow-up, which also enabled us to identify a population-based, age and gender matched comparison cohort. We obtained data on study endpoints from the same data sources, which minimised differential misclassification. As non-Caucasians have higher rates of DM [32] the risk posed by HIV and HAART may be overestimated in studies primarily including non-Caucasian individuals. To minimise confounding posed by differences in ethnicity between groups (HIV-infected/comparison cohort), we restricted the analysis to native individuals. We furthermore adjusted for potential confounding factors and evaluated clinical relevant effect modifications. We are not aware of other studies with a similar design.

Due to the study design we had no access to fasting glucose measurements and had to rely on hospital registry-based discharge diagnoses, diagnosis from outpatient clinics and data on redeemed prescriptions of anti-diabetic drugs. As non-fasting glucose
concentration is measured at least once yearly in Danish HIV-clinics, HIV-infected individuals might be prone to an earlier DM diagnosis than the general population. However, without using regular fasting glucose measurements for both groups, the true DM incidence could be underestimated, and the categorisation of the individual as type 2 DM might be delayed for several years. As life style modifications are first line treatment for type 2 DM, individuals in our study may remain unregistered in this period, which makes a window for withdrawal and switch of antiretroviral drugs with the risk of reversed causality problems [7]. Furthermore, as we used an intent-to-continue-treatment approach the associations seen were related to individuals who had ever been exposed to the drugs rather than to those who are currently exposed. For drugs that might have been used for shorter periods in the earlier years, this could bias the results. We used DM in general as our primary endpoint as type 1 and type 2 DM could not be unambiguously discriminated in the registries [31,33]. A similar approach has been used by others [31] and a robustness analyses demonstrated that our results were not severely biased by this design.

As lipoatrophy was defined as fat redistribution and registered in DHCS without standardized assessments such as DEXA, MRI or CT scans, lipoatrophy could be a weak predictor of true lipodystrophy. Additionally, BMI was estimated at index date. As the weight can change dramatically over years, especially in the HIV-infected population, we are aware that the absence of the weight dynamic could have affected the results; however, using time-dependent measures for BMI did not modify the findings in a recent French study [22]. Finally, as we had no data on socioeconomic status, level of exercise, family history of DM or

Table 1. Basic characteristics for Danish born HIV-infected individuals and comparison cohort individuals.

|                              | Danish born HIV-infected individuals | Comparison cohort individuals |
|------------------------------|-------------------------------------|-------------------------------|
| (N = 3,540)                  | (N = 14,160)                        |                               |
| Age at index date, median years (IQR) | 38.7 (32.2–46.6)                   | 38.7 (32.2–46.6)              |
| Male gender, N (%)           | 2,977 (84.1)                        | 11,908 (84.1)                 |
| Caucasian race, N (%)        | 3,451 (97.5)                        | –                             |
| Body mass index (BMI) at index date: |                                    |                               |
| Underweight (BMI: <18.5), N (%) | 199 (5.6)                           | –                             |
| Normal weight (BMI: 18.5–24.9), N (%) | 1,651 (46.6)                       | –                             |
| Overweight (BMI: 25.0–29.9), N (%) | 539 (15.2)                         | –                             |
| Obesity (BMI: >30.0), N (%)  | 104 (2.9)                           | –                             |
| Missing data on BMI, N (%)   | 1,047 (29.6)                        | –                             |
| Infection mode:              |                                    |                               |
| MSM, N (%)                   | 1,881 (53.1)                        | –                             |
| Heterosexual contact, N (%)  | 1,009 (28.3)                        | –                             |
| Intravenous drug abuse, N (%)| 453 (12.8)                          | –                             |
| Other/unknown, N (%)         | 197 (6.6)                           | –                             |
| Hepatitis C co-infection or intravenous drug abuse, N (%) | 677 (19.1) | – |
| No of patients diagnosed with HIV-infection prior to 1996, N (%) | 1,674 (44.5) | – |
| No of patients with AIDS diagnosed prior to index date, N (%) | 367 (10.4) | – |
| CD4 cell count at index date, median cells/μL (IQR) | 300 (120–497) | – |
| Duration of follow-up, PYR  | 28,342                               | 136,365.5                     |
| Duration of follow-up, median-years (IQR) | 8.0 (3.4–14.0) | 11.2 (5.5–14.0) |
| Death during follow-up, N (%)| 845 (23.9)                           | 643 (4.5)                     |
| Emigration during follow-up, N (%) | 67 (1.9) | 140 (1.0) |
| Lost to follow-up, N (%)     | 2 (0.1)                              | 2 (0.0)                       |
| New-onset diabetes mellitus (DM) after index date, N (%) | 105 (3.0) | 528 (3.7) |
| Type 1 DM, N (%)             | 10 (0.3)                             | 17 (0.1)                      |
| Type 2 DM, N (%)             | 95 (2.7)                             | 511 (3.6)                     |
| Age at DM diagnosis, median years (IQR) | 52.6 (43.5–60.6) | 54.0 (46.6–61.0) |
| Lipoatrophy prior to DM diagnosis, N (%) | 21 (20.0) | – |
| Initiated HAART prior to DM diagnosis, N (%) | 90 (85.7) | – |
| CD4 cell count at DM diagnosis, median cells/μL (IQR) | 437 (199–655) | – |
| IR of diabetes mellitus per 1,000 PYR (95% CI) | 3.70 (3.06–4.49) | 3.87 (3.56–4.22) |

**Abbreviations:** IQR: Interquartile range; IR: Incidence Rate; 95% CI: 95% Confidence Interval; PYR: Person-years; MSM: men who have sex with men; DM: Diabetes Mellitus; HAART: Highly Active Antiretroviral Therapy. doi:10.1371/journal.pone.0044575.t001
information on BMI for the comparison cohort, we could not adjust for these potential confounders.

Despite the extensive literature on metabolic alterations in HIV-infected individuals, no consensus regarding risk of DM has been reached. In a recent French study (APROCO-COPILOTE/1997–1999), Capeau et al. [22] found a markedly higher incidence of DM (14.1 per 1,000 PYR) than we did and what was reported for the HIV-uninfected French population, the European general population and other HIV-infected populations (4–6/1,000 PYR) [22]. However, measures of incidence might vary due to differences in factors such as age, gender, race and BMI. In comparison a study from the MACS cohort [19] (1999–2003) found that HIV-infected

Figure 1. Cumulative incidence of diabetes mellitus in Danish born HIV-infected individuals compared to a Danish born comparison cohort. (Index date: the latest of 1 January 1996 or date of HIV diagnosis).
doi:10.1371/journal.pone.0044575.g001

Table 2. Risk of diabetes mellitus (DM) in Danish born HIV-infected individuals compared to Danish born comparison cohort individuals.

|                         | DM events/PYR for HIV-infected individuals | DM events/PYR for comparison cohort individuals | IRR of diabetes mellitus in Danish born HIV-infected individuals versus comparison cohort individuals |
|-------------------------|-------------------------------------------|-----------------------------------------------|-----------------------------------------------------------------------------------------------------------------|
|                         |                                           |                                               | Unadjusted IRR (95% CI) | Adjusted* IRR (95% CI) |
| Diabetes mellitus:      |                                           |                                               | 0.96 (0.78–1.18)       | 1.02 (0.83–1.26)       |
| Stratified on gender:   |                                           |                                               |                        |                        |
| Males:                  | 90/23,308                                 | 467/112,690                                  | 0.93 (0.74–1.17)       | 0.99 (0.79–1.25)       |
| Females:                | 15/5,034                                  | 61/23,675                                    | 1.16 (0.66–2.03)       | 1.22 (0.69–2.15)       |
| Analysed according to split in calendar time (time-updated variable) |                                           |                                               |                        |                        |
| 01.01.1996–31.12.1998   | 18/4,768                                  | 29/20,992                                    | 2.73 (1.52–4.92)       | 2.83 (1.57–5.09)       |
| 01.01.1999–01.01.2010    | 87/23,574                                 | 499/115,374                                  | 0.85 (0.68–1.07)       | 0.90 (0.72–1.13)       |
| Analysed according to HAART initiation and split in calendar time (Time-updated variables) |                                           |                                               |                        |                        |
| 01.01.1996–31.12.1998   |                                           |                                               | Unadjusted IRR (95% CI) | Adjusted** IRR (95% CI) |
| NON-HAART               | 8/2,904                                   | 16/13,223                                    | 2.28 (0.97–5.32)       | 2.40 (1.03–5.62)       |
| HAART                   | 10/1,864                                  | 13/7,768                                     | 3.21 (1.41–7.31)       | 3.24 (1.42–7.39)       |
| 01.01.1999–01.01.2010    |                                           |                                               |                        |                        |
| Non-HAART               | 7/5,028                                   | 122/30,221                                   | 0.34 (0.16–0.74)       | 0.45 (0.21–0.96)       |
| HAART                   | 80/18,546                                 | 377/85,153                                   | 0.97 (0.77–1.24)       | 1.00 (0.79–1.28)       |

Abbreviations: IRR: Incidence rate ratio; 95% CI: Confidence Interval; PYR: Person-years; HAART: Highly Active Antiretroviral Therapy.

*Adjusted for age (split at 30, 35, 40, 45, 50, 55, 60 and 65), gender and calendar time (split at 3, 5, 8 and 11 years after January 1, 1996).

**Analysed separately according to split in calendar time (split at 3 years after January 1, 1996) and adjusted for age (split at 30, 35, 40, 45, 50, 55, 60, and 65) and gender. For time periods after 31 December 1998 the analysis were further adjusted for calendar time (split at 5, 8, 11 years after January 1, 1996).

doi:10.1371/journal.pone.0044575.t002
Table 3. Impact of body mass index (BMI), age and lipoatrophy on risk of diabetes mellitus in Danish born HIV-infected individuals.

| Baseline variables: | DM events (105) | PYR (28,342) | Unadjusted IRR (95% CI) | Adjusted* IRR (95% CI) |
|---------------------|----------------|-------------|------------------------|------------------------|
| Body mass index (BMI): |               |             |                        |                        |
| Underweight (BMI: <18.5) | 3            | 1,513       | 0.85 (0.26–2.77)       | 0.89 (0.27–2.90)       |
| Normal weight (BMI: 18.5–24.9) | 36           | 15,466      | Ref (1)                | Ref (1)                |
| Overweight (BMI: 25.0–29.9) | 22           | 5,239       | 1. 80 (1.06–3.07)      | 1.60 (0.94–2.73)       |
| Obesity (BMI: >30.0) | 21           | 899         | 10.04 (5.86–17.20)     | 9.25 (5.37–15.94)      |
| Time-updated variables: |               |             |                        |                        |
| Age periods (years): |               |             |                        |                        |
| 0–29                | 2             | 1,776       | Ref (1)                | Ref (1)                |
| 30–39               | 14            | 8,576       | 1.45 (0.33–6.38)       | 1.10 (0.25–4.85)       |
| 40–49               | 30            | 9,821       | 2.71 (0.65–11.35)      | 2.01 (0.48–8.47)       |
| 50–59               | 32            | 5,821       | 4.88 (1.17–20.37)      | 3.73 (0.89–15.66)      |
| 60+                 | 27            | 2,348       | 10.21 (2.43–42.95)     | 8.16 (1.91–34.74)      |
| Lipoatrophy:        |               |             |                        |                        |
| No lipoatrophy      | 84            | 26,182      | Ref (1)                | Ref (1)                |
| Lipoatrophy         | 21            | 2,160       | 3.03 (1.88–4.89)       | 2.30 (1.39–3.80)       |

Abbreviations: IRR: Incidence rate ratio; 95% CI: Confidence Interval; PYR: Person-years; *Adjusted for age (split at 30, 35, 40, 45, 50, 55, 60, and 65), gender and calendar time (split at 3, 5, 8 and 11 years after January 1, 1996) and Hepatitis C Infection or Intravenous drug abuse.

doi:10.1371/journal.pone.0044575.t003

men on HAART compared to HIV-negative men had a more than 4 times increased risk of developing DM when adjusting for age and BMI, whereas the incidence of DM in the HIV-infected individuals not on HAART did not differ substantially from that of HIV-negative individuals. These findings contrast our results from the years subsequent to 31 December 1998 as well as the gender specific results from the WIHS (2001–2003 and 2002–2004), MS and CHAMPS cohort (2000–2005) [21,23,34], that found no statistically significant impact of HIV or HAART on risk of DM. In addition, the VACS cohort (2000–2005) [8] even found that HIV was associated with a statistically significant lower prevalence of DM (adjusted odds ratio: 0.84; 95% CI 0.72–0.97).

In the years 1996–1998 we found a 2.83 times higher risk of DM in the HIV-infected population than in the comparison cohort. As the increased risk was observed both in the period before and in the period after HAART initiation, the effect seems not only associated with the use of toxic antiretroviral drug-regimens. This early period reflects a population considerably affected by the HIV infection and therefore differs from the later period. But, drugs with potentially diabetogenic effects such as Pentamidin Isothionate, used for the prevention and treatment of Pneumocystis Jirovici, and mono-therapy with first generation antiretroviral drugs like stavudine and indinavir, were also used in the pre-HAART era. In addition, it must be emphasized that the observed increased risk of DM in 1996–1998 may rely on a small number of events. In the study by Capeau et al. [22] incidence peaked in 1999–2000 and gradually decreased thereafter. This was partly explained by exposure to high levels of first generation antiretroviral drugs and to lipodystrophy. Similarly, De Wit et al. (the D:A:D-study) [9] also found that earlier calendar years (1999–2000) was associated with a higher risk of DM. However, contrary to the ongoing design of our study, in which patients were consecutively recruited during the entire study period, these studies consisted of closed cohorts [9,22].

After 1998 we found that HIV-infected individuals not on HAART had a decreased risk of DM which is in accordance with the non-significant trend found by Tien et al. [21]. A large Danish population-based survey (Inter99, 1999–2000) showed a higher proportion of overweight (39.5%) and obesity (16.3%) in the general population (age 30–60 years) than in our HIV-infected cohort [6]. This potentially lower BMI in our HIV-infected cohort compared to the general population could have lead to an underestimation of the impact of HIV infection per se. We therefore presume that the decreased risk of DM in the non-HAART period could be due to lower weight of the untreated individuals and less focus on DM before start of HAART; however, an effect related purely to small numbers cannot be excluded.

Due to a rising prevalence of overweight and obesity in developed countries, the prevalence of DM is increasing rapidly [6,35]. Our findings of an increased risk of DM with increasing age and BMI indicate that traditional risk factors seem to apply in the same way in HIV-infected individuals as for the background population. We therefore suggest that HIV patients are screened for DM in accordance with local general guidelines.

Several studies have found an increased risk of DM in HIV-infected individuals on HAART compared to HAART-naïve individuals [7–8,18–19,24]. In contrast, studies of the cumulative effect of HAART as well as individual drug classes have shown conflicting results [7,9–10,18–23,34]. We observed an increased risk of DM in HIV-infected individuals treated with HAART when compared to HIV-infected individuals not on HAART. However, this effect does not stem from a higher risk of DM in HAART treated patients compared to the general population, but relies on a lower incidence of DM in the non-HAART period. We saw an increased risk of DM in the early calendar period which is
in accordance with the use of indinavir, saquinavir, stavudine and didanosine in the early HAART era. This observation is in accordance with the results by Capeau et al. [22].

In some studies treatment with PIs in general has been found associated with higher risk of DM [10,18]. This contrasts our observations of no increased DM risk. The discrepancies might rely on marked variation in risk of DM between different PIs as the effects of individual drugs might be diluted when analysing PI as a class. Prior studies have indicated a direct blockage of GLUT-4 induced by indinavir [36–37] and thus an acute onset and possible reversible effect after drug discontinuation. In addition, Ledergerber et al. [7] examined 6,513 HIV-infected individuals from the Swiss Cohort Study and found a higher risk of DM in association with indinavir, which is consistent with the trend found in our study and the results of others [11,20,22].

Some NRTIs have been proposed to be associated with a higher risk of DM [7,9,11,19,22]. Ledergerber et al. [7] found a strong association between current therapy with NRTI, and risk of incident DM. Stavudine has consistently been associated with a higher risk of lipoatrophy, hyperinsulinemia and DM [9,11,19–20,22]. Consistent with our results the APROCOPILOTE-study and the D:A:D-study [9,22] found an increased risk of DM in association with stavudine and didanosine as well as a significant association with lipodystrophy. However, adjusting for lipodystrophy did not modify the relationship substantially, which might indicate an effect of NRTIs independent of lipodystrophy [9].

In conclusion, native HIV-infected individuals have no increased risk of DM compared to native individuals from the background population after year 1998. Some antiretroviral drugs that are only used infrequently in modern antiretroviral treatment seem to increase the risk of DM.

### Table 4. Impact of specific antiretroviral drugs on risk of diabetes mellitus (DM) in Danish born HIV-infected individuals on HAART.

| Time-updated variables: | DM events (90) | PYR (20,410) | Unadjusted IRR (95% CI) | Adjusted* IRR (95% CI) |
|-------------------------|----------------|--------------|-------------------------|------------------------|
| **PROTEASE INHIBITORS:** |                |              |                         |                        |
| Ever exposed to PI      |                |              |                         |                        |
| 71                      | 16,238         | 0.96 (0.58–1.59) | 0.95 (0.56–1.62)         |                        |
| Ever exposed to indinavir|                |              |                         |                        |
| 44                      | 8,228          | 1.42 (0.94–2.14) | 1.38 (0.91–2.11)         |                        |
| Ever exposed to saquinavir|              |              |                         |                        |
| 39                      | 6,854          | 1.51 (1.00–2.29) | 1.53 (1.01–2.34)         |                        |
| Ever exposed to nelfinavir|              |              |                         |                        |
| 20                      | 4,946          | 0.89 (0.54–1.47) | 0.95 (0.57–1.57)         |                        |
| Ever exposed to atazanavir|              |              |                         |                        |
| 11                      | 2,283          | 1.11 (0.59–2.08) | 0.95 (0.49–1.88)         |                        |
| Ever exposed to ritonavir|              |              |                         |                        |
| 55                      | 11,932         | 1.12 (0.73–1.71) | 1.11 (0.72–1.70)         |                        |
| Ever exposed to lopinavir/ritonavir| |              |                         |                        |
| 14                      | 3,242          | 0.98 (0.55–1.73) | 0.94 (0.52–1.69)         |                        |
| **NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS:** |    |              |                         |                        |
| Ever exposed to stavudine|              |              |                         |                        |
| 46                      | 13,561         | Ref (1)      | Ref (1)                 |                        |
| Ever exposed to zidovudine|              |              |                         |                        |
| 8                       | 2,112          | Ref (1)      | 1.81 (1.19–2.75)         |                        |
| Ever exposed to dianosine|              |              |                         |                        |
| 34                      | 5,547          | 1.63 (1.06–2.49) | 1.52 (0.99–2.34)         |                        |
| Ever exposed to abacavir|              |              |                         |                        |
| 48                      | 11,831         | Ref (1)      | 1.09 (0.68–1.73)         |                        |
| Ever exposed to tenofovir|              |              |                         |                        |
| 17                      | 3,534          | 1.11 (0.66–1.89) | 1.06 (0.59–1.91)         |                        |
| Ever exposed to lamivudine|              |              |                         |                        |
| 86                      | 19,297         | 1.24 (0.46–3.38) | 1.15 (0.42–3.17)         |                        |

Abbreviations: IRR: Incidence rate ratio; 95% CI: Confidence Interval; PYR: Person-years; Ref: Reference group = HIV-infected individuals on HAART not exposed to the investigated antiretroviral drug.

*Adjusted for age (split at 30, 40, 50 and 60), gender, calendar time (split at 3, 5, 8 and 11 years after January 1, 1996), Hepatitis C infection or intravenous drug abuse, and CD4 cell count (split at date of CD4 cell count >200 cells/μL after start of HAART).

doi:10.1371/journal.pone.0044575.t004
Supporting Information

Appendix S1 Diagnostic codes of diabetes mellitus (ICD 8 and ICD 10 codes).

Appendix S2 ATC codes of antidiabetic drugs (Insulin and analogues, and oral antidiabetic drugs).

Appendix S3 Definition and grouping of body mass index.

Acknowledgments

We are grateful to the staff of our clinical departments for their continuous support and enthusiasm.

References

1. Calza L, Manfredi R, Chiudò F (2004) Insulin resistance and diabetes mellitus in HIV-infected patients receiving antiretroviral therapy: Metab Syndr Relat Disord. 2: 241–250.

2. Grinspoon S (2003) Mechanisms and strategies for insulin resistance in acquired immune deficiency syndrome. Clin Infect Dis. 37: 85–90.

3. Safrin S, Grunder G (1999) Fat distribution and metabolic changes in patients with HIV infection. AIDS. 13: 2493–2505.

4. Antiretroviral Therapy Cohort collaboration (2008) Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 372: 293–299.

5. Lohse N, Hansen AB, Pedersen G, Krönborg G, Gerstoft J, et al. (2007) Survival of persons with and without HIV infection in Denmark 1995–2005. Ann Intern Med. 146: 87–95.

6. Glümer C, Carstensen B, Sandbaek A, Lauritzen T, Jørgensen T, et al. (2004) A Danish diabetes risk score for targeted screening: the Inter99 study. Diabetes care. 27: 727–733.

7. Ledegerger B, Furrer H, Rickert M, Lehmann R, Elzi L, et al. (2007) Swiss HIV Cohort Study. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. Clin Infect Dis. 43: 111–119.

8. Butt AA, McGinnis K, Rodríguez-Barradas MC, Crystal S, Sinheroff M, et al. (2009) Veterans Aging Cohort Study. HIV infection and the risk of diabetes mellitus. AIDS. 23: 1227–1234.

9. De Wit S, Sabin CA, Weber R, Worm SW, Reiss P, et al. (2008) Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. Diabetes Care. 31: 1224–1229.

10. Lo YC, Chen MY, Sheng WH, Hsieh SM, Sun HY, et al. (2009) Risk factors for incident diabetes mellitus among HIV-infected patients receiving combination antiretroviral therapy in Taiwan: a case-control study. HIV Med. 10: 302–309.

11. Brambilla AM, Novati R, Calori G, Meneghini E, Vachini D, et al. (2003) Stavudine or indinavir-containing regimens are associated with an increased risk of diabetes mellitus in HIV-infected individuals. AIDS. 17: 1993–1995.

12. Vinszaghvashala C, Chen L, Raghavan S, Tedaldi E (2005) Prevalence of diabetes mellitus and dyslipidemia among antiretroviral naive patients co-infected with hepatitis C virus (HCV) and HIV-1 compared to patients without co-infection. J Infect. 55: 331–337.

13. Howard AA, Hoover DR, Anastos K, Wu X, Shu Q, et al. (2010) The effects of opiate use and hepatitis C virus infection on risk of diabetes mellitus in the Women’s Intergenerational HIV Study. J Acquir Immune Defic Syndr. 54: 152–159.

14. Lymphkin MM (1997) Reports of diabetes and hyperglycemia in patients receiving protease inhibitors for the treatment of human immunodeficiency virus (HIV). FDA Public Health Advisory, June 21.

15. Dubé MP, Johnson DL, Currier JS, Leedom JM (1997) Protease inhibitor-associated hyperglycemia. Lancet. 350: 713–714.

16. Walli R, Herriot O, Michl GM, Demans T, Jager H, et al. (1998) Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS. 12: F167–F173.

17. Tsiodras S, Mantzoros C, Hammer S, Samore M (2008) Effects of protease inhibitors on hyperglycemia, hyperlipidemia and lipodystrophy: a 5-year-cohort study. Arch Intern Med. 160: 2050–2056.

18. Justman JE, Benning L, Danoff A, Minkoff H, Levine A, et al. (2003) Protease Inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr. 32: 298–302.

19. Brown TT, Cole SR, Li X, Kingsley LA, Palella FJ, et al. (2005) Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Ann Intern Med. 145: 1259–1264.

20. Brown TT, Li X, Cole SR, Kingsley LA, Palella FJ, et al. (2005) Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS. 19: 1375–1383.

21. Tien PC, Schneider MF, Cole SR, Levine AM, Cohen H, et al. (2007) Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women’s Intergenerational HIV Study. AIDS. 21: 1739–1745.

22. Capeau J, Boulèvaloup V, Katlama C, Bastard JP, Guyédi Y, et al. ANRS CO10 APROCO-COPOLITE. Cohort Study Group (2012) Ten-year diabetes incidence in 1096 HIV-infected patients started on a combination antiretroviral treatment. AIDS. 26: 303–314.

23. Poulby S, Norris-Moore M, Schoenbaum EE, Klein RS, Arsten JE, et al. (2011) Incident hyperglycemia among older adults with or at risk for HIV infection. Antivir Ther. 16: 181–188.

24. Idejolla J, Ravindra’n GD, D’Souza J, Singh G, Furruqh S (2011) Diabetes mellitus, insulin resistance, and metabolic syndrome in HIV-positive patients in South India. Int J Gen Med. 4: 73–78.

25. Statistics Denmark. Population and Election. Available: http://www.dst.dk/ Homepage/Statistics/Key_indicators/Population/pop.aspx. Accessed 2011 Oct 9.

26. Lohse N, Hansen AB, Jensen-Fangl S, Krönborg G, Kviisland B, et al. (2005) Demographics of HIV-1 infection in Denmark: results from the Danish HIV Cohort Study. Scand J Infect Dis. 37: 335–343.

27. Obel N, Esgin FN, Rasmussen LD, Larsen LV, Omland LH, et al. (2009) Cohort profile: the Danish HIV Cohort Study. Int J Epidemiol. 38: 1202–1206.

28. Pedersen CB (2011) The Danish Civil Registration System. Scand J Pub Health. 39: 92–95.

29. Andersen TF, Madsen M, Jørgensen J, Meldemkiper J, Olsen JH (1999) The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull. 46: 265–268.

30. Killemorens HW, Sorensen HT, Hallas J (2011) The Danish National Prescription Registry. Scand J Public Health. 39: 38–41.

31. Petersen I, Nielsen MM, Beck-Nielsen H, Christensen K (2011) No evidence of a higher 10 year period prevalence of diabetes among 77,885 twins compared with 215,263 singletons from the Danish birth cohorts 1910–1989. Diabetologia. 54: 2016–2024.

32. Harris MI (1991) Epidemiological correlates of NIDDM in Hispanics, whites, and blacks in the U.S. population. Diabetes care. 14: 639–640.

33. Hoomel K, Rasmussen S, Madsen M, Kømper AL (2010) The Danish Registry on Regular Dialysis and Transplantation: completeness and validity of incident patient registration. Nephrol Dial Transplant. 25: 947–951.

34. Danoff A, Justman J, Mulligan K, Hosen N, Robinson E, et al. (2005) Oral glucose tolerance and insulin sensitivity are unaffected by HIV infection or antiretroviral therapy in overweight women. J Acquir Immune Defic Syndr. 39: 55–62.

35. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, et al. (2001) The continuing epidemics of obesity and diabetes in the United States. JAMA. 286: 1195–1200.

36. Noor MA, Seneviratne T, Aweeka FT, Lo JC, Schwarz JM, et al. (2001) NIDDM prevalence and metabolic syndrome in HIV-seropositive patients. J Acquir Immune Defic Syndr. 27: 555–559.

37. Noor MA, Seneviratne T, Aweeka FT, Lo JC, Schwarz JM, et al. (2001) NIDDM prevalence and metabolic syndrome in HIV-seropositive patients. J Acquir Immune Defic Syndr. 27: 555–559.

38. Noor MA, Seneviratne T, Aweeka FT, Lo JC, Schwarz JM, et al. (2001) NIDDM prevalence and metabolic syndrome in HIV-seropositive patients. J Acquir Immune Defic Syndr. 27: 555–559.

39. Noor MA, Seneviratne T, Aweeka FT, Lo JC, Schwarz JM, et al. (2001) NIDDM prevalence and metabolic syndrome in HIV-seropositive patients. J Acquir Immune Defic Syndr. 27: 555–559.

40. Noor MA, Seneviratne T, Aweeka FT, Lo JC, Schwarz JM, et al. (2001) NIDDM prevalence and metabolic syndrome in HIV-seropositive patients. J Acquir Immune Defic Syndr. 27: 555–559.